William D. Humphries's most recent trade in Aclaris Therapeutics Inc was a trade of 42,350 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 42,350 | 42,350 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 11,580 | 11,580 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2025 | 4,793 | 33,525 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2025 | 4,793 | 0 | - | - | Restricted Stock Units | |
| Clearside Biomedical Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 4,793 | 4,793 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 28,732 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 0 | - | - | Restricted Stock Units | |
| STRATA Skin Sciences Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 1.03 per share. | 05 Jul 2023 | 36,408 | 109,724 (0%) | 0% | 1.0 | 37,500 | SSKN Common Stock |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,660 | 4,660 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 24,072 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 0 | - | - | Restricted Stock Units | |
| Clearside Biomedical Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 4,507 | 4,507 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | William D. Humphries | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 19,565 (0%) | 0% | - | Common Stock | |
| STRATA Skin Sciences Inc | William D. Humphries | Director | Purchase of securities on an exchange or from another person at price $ 1.73 per share. | 25 Mar 2022 | 16,950 | 484,440 (1%) | 0% | 1.7 | 29,385 | SSKN Common Stock |
| STRATA Skin Sciences Inc | William D. Humphries | Director | Purchase of securities on an exchange or from another person at price $ 1.58 per share. | 24 Mar 2022 | 14,783 | 467,490 (1%) | 0% | 1.6 | 23,387 | SSKN Common Stock |
| Clearside Biomedical Inc | William D. Humphries | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.15 per share. | 10 Jan 2022 | 22,727 | 28,313 (0%) | 0% | 0.1 | 3,409 | Common Stock |
| Clearside Biomedical Inc | William D. Humphries | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2022 | 22,727 | 0 | - | - | Stock Option (right to buy) | |
| STRATA Skin Sciences Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 411,124 | 452,707 | - | - | Non-Qualified Stock Option Agreement for SSKN Common Stock | |
| STRATA Skin Sciences Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 21,583 | 41,583 (0%) | 0% | 0 | SSKN Common Stock | |
| STRATA Skin Sciences Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 20,000 | 20,000 (0%) | 0% | 0 | SSKN Common Stock | |
| Clearside Biomedical Inc | William D. Humphries | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (right to buy) |